WO2009013846A1 - 前立腺肥大に伴う下部尿路症状の改善用医薬組成物 - Google Patents

前立腺肥大に伴う下部尿路症状の改善用医薬組成物 Download PDF

Info

Publication number
WO2009013846A1
WO2009013846A1 PCT/JP2007/074717 JP2007074717W WO2009013846A1 WO 2009013846 A1 WO2009013846 A1 WO 2009013846A1 JP 2007074717 W JP2007074717 W JP 2007074717W WO 2009013846 A1 WO2009013846 A1 WO 2009013846A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostatomegaly
pharmaceutical composition
urinary tract
symptom associated
lower urinary
Prior art date
Application number
PCT/JP2007/074717
Other languages
English (en)
French (fr)
Inventor
Hidehiro Kakizaki
Masaki Yoshida
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40281108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009013846(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to CN200780053847A priority Critical patent/CN101754760A/zh
Priority to CA2697137A priority patent/CA2697137A1/en
Priority to EP07851069A priority patent/EP2172201A4/en
Priority to JP2009524370A priority patent/JPWO2009013846A1/ja
Publication of WO2009013846A1 publication Critical patent/WO2009013846A1/ja
Priority to US12/688,426 priority patent/US20100331361A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　(R)-5-(2-{[2-(2-エトキシフェノキシ)エチル]アミノ}プロピル)-2-メトキシベンゼン-1-スルホンアミド（タムスロシン）又はその製薬学的に許容される塩、及び、(1S)-1-フェニル-1,2,3,4-テトラヒドロイソキノリン-2-カルボン酸 (3R)-キヌクリジン-3-イルエステル（ソリフェナシン）又はその製薬学的に許容される塩を有効成分とする医薬組成物、特に前立腺肥大に伴う下部尿路症状の改善用医薬組成物を提供する。また、前立腺肥大に伴う下部尿路症状の改善のためのタムスロシンまたはその製薬学的に許容される塩、及び、ソリフェナシンまたはその製薬学的に許容される塩の併用、及び併用療法を提供する。
PCT/JP2007/074717 2007-07-20 2007-12-21 前立腺肥大に伴う下部尿路症状の改善用医薬組成物 WO2009013846A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN200780053847A CN101754760A (zh) 2007-07-20 2007-12-21 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
CA2697137A CA2697137A1 (en) 2007-07-20 2007-12-21 Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
EP07851069A EP2172201A4 (en) 2007-07-20 2007-12-21 PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS RELATED TO PROSTATE GAL
JP2009524370A JPWO2009013846A1 (ja) 2007-07-20 2007-12-21 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
US12/688,426 US20100331361A1 (en) 2007-07-20 2010-01-15 Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92999607P 2007-07-20 2007-07-20
US60/929996 2007-07-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/688,426 Continuation-In-Part US20100331361A1 (en) 2007-07-20 2010-01-15 Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy

Publications (1)

Publication Number Publication Date
WO2009013846A1 true WO2009013846A1 (ja) 2009-01-29

Family

ID=40281108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074717 WO2009013846A1 (ja) 2007-07-20 2007-12-21 前立腺肥大に伴う下部尿路症状の改善用医薬組成物

Country Status (8)

Country Link
US (1) US20100331361A1 (ja)
EP (1) EP2172201A4 (ja)
JP (1) JPWO2009013846A1 (ja)
KR (1) KR20100040294A (ja)
CN (1) CN101754760A (ja)
CA (1) CA2697137A1 (ja)
TW (1) TW200904424A (ja)
WO (1) WO2009013846A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010090172A1 (ja) 2009-02-04 2010-08-12 アステラス製薬株式会社 経口投与用医薬組成物
JP2016508958A (ja) * 2012-10-15 2016-03-24 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． 健康を促進するための緑茶抽出物と紅茶抽出物との混合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102743757A (zh) * 2012-07-09 2012-10-24 张家华 治疗膀胱流出道梗阻所致膀胱活动过度的药物
CN106562968B (zh) * 2015-10-13 2019-08-13 南京华威医药科技集团有限公司 包含盐酸坦洛辛和琥珀酸索利那新的药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703063A (en) 1980-02-08 1987-10-27 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine derivatives and process of producing them
WO1996020194A1 (fr) 1994-12-28 1996-07-04 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
JP2001114679A (ja) * 1999-08-09 2001-04-24 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
WO2003103659A1 (ja) * 2002-06-07 2003-12-18 山之内製薬株式会社 過活動膀胱治療剤
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192769C (zh) * 1999-08-09 2005-03-16 山之内制药株式会社 下部尿路症治疗用医药组合物
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
PT1806136E (pt) * 2004-10-06 2012-03-08 Kissei Pharmaceutical Composição medicamentosa para a prevenção da transição para o tratamento operatório da hipertrofia prostática
EP2181707A1 (en) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703063A (en) 1980-02-08 1987-10-27 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine derivatives and process of producing them
WO1996020194A1 (fr) 1994-12-28 1996-07-04 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
JP2001114679A (ja) * 1999-08-09 2001-04-24 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
WO2003103659A1 (ja) * 2002-06-07 2003-12-18 山之内製薬株式会社 過活動膀胱治療剤
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOLIA PHARMACOLOGICA JAPONICA, vol. 12, 2003, pages 331
See also references of EP2172201A4 *
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 296, no. 19, 2006, pages 2319
THE JOURNAL OF UROLOGY, vol. 174, 2005, pages 1334

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010090172A1 (ja) 2009-02-04 2010-08-12 アステラス製薬株式会社 経口投与用医薬組成物
EP2394648A4 (en) * 2009-02-04 2012-08-29 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
JP5553026B2 (ja) * 2009-02-04 2014-07-16 アステラス製薬株式会社 経口投与用医薬組成物
US9198904B2 (en) 2009-02-04 2015-12-01 Astellas Pharma Inc. Pharmaceutical composition for oral administration
EP2394648B1 (en) 2009-02-04 2016-08-31 Astellas Pharma Inc. Pharmaceutical composition for oral administration
JP2016508958A (ja) * 2012-10-15 2016-03-24 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． 健康を促進するための緑茶抽出物と紅茶抽出物との混合物

Also Published As

Publication number Publication date
KR20100040294A (ko) 2010-04-19
CA2697137A1 (en) 2009-01-29
EP2172201A4 (en) 2011-07-06
TW200904424A (en) 2009-02-01
JPWO2009013846A1 (ja) 2010-10-07
EP2172201A1 (en) 2010-04-07
US20100331361A1 (en) 2010-12-30
CN101754760A (zh) 2010-06-23

Similar Documents

Publication Publication Date Title
WO2009057685A1 (ja) 過活動膀胱治療用医薬組成物
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007087431A3 (en) Sublingual fentanyl spray
RU2015117267A (ru) Замещенные соединения амида
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
WO2007149283A3 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI
EP2033954A4 (en) COMPOUND 6- (4-OXOQUINOLIN-SUBSTITUTED BENZYL) AND USE THEREOF AS INHIBITOR OF HIV INTEGRASE
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
EP1902715A3 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
WO2009013846A1 (ja) 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
WO2009103476A8 (en) Antitumoral agents with a benzophenanthridine structure and formulations containing them
EP2263678A3 (en) Cladribine regimen for treating Multiple Sclerosis
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP2392335A3 (en) Use of 24-norUDCA
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
EP1152002A4 (en) PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2005070903A3 (en) Sulphonamide substituted triazines as chemokine receptor modulators
WO2011038380A3 (en) Combination

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780053847.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07851069

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009524370

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107001264

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2697137

Country of ref document: CA

Ref document number: 2007851069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 382/CHENP/2010

Country of ref document: IN

Ref document number: MX/A/2010/000805

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE